| 戴宇翃,王建华,付 强.盐酸埃克替尼治疗190例晚期非小细胞肺癌疗效及不良反应[J].中国肿瘤,2015,24(2):149-154. |
| 盐酸埃克替尼治疗190例晚期非小细胞肺癌疗效及不良反应 |
| The Efficacy and Toxicitiy of Icotinib in the Treatment for 190 Cases with Advanced NSCLC |
| 投稿时间：2014-05-30 |
| DOI：10.11735/j.issn.1004-0242.2015.02.A015 |
|
 |
| 中文关键词: 非小细胞肺癌 EGFR-TKI 埃克替尼 靶向治疗 不良反应 |
| 英文关键词:non-small cell lung cancer EGFR-TKI icotinib targeted therapy toxicity |
| 基金项目: |
|
| 摘要点击次数: 2458 |
| 全文下载次数: 1060 |
| 中文摘要: |
| 摘 要：［目的］ 探讨盐酸埃克替尼治疗晚期非小细胞肺癌患者的疗效和安全性。［方法］ 对190例单药盐酸埃克替尼治疗的患者进行随访，中位随访时间为21个月，记录有效性及不良反应数据。［结果］ 全组中位PFS为8.1个月（95%CI：6.4~9.8个月），中位OS为14.1个月（95%CI：11.5~16.7个月），DCR为71.6%（136/190），ORR为35.3%（67/190）。女性、不吸烟患者的PFS优于男性，吸烟患者。而PS评分低及埃克替尼用于二线及以上治疗者表现出更长的PFS及OS。治疗相关不良反应主要为皮疹（38.9%）、腹泻（13.7%）、转氨酶升高（11.1%）及上腹部不适（7.9%），1例出现肺间质样改变。［结论］ 埃克替尼治疗晚期非小细胞肺癌具有较好的疗效及安全性。 |
| 英文摘要: |
| Abstract：［Purpose］ To investigate the efficacy and toxicity of icotinib hydrochloride in the treatment for patients with advanced non-small cell lung cancer (NSCLC).［Methods］ One hundred and ninety cases with advanced NSCLC treated with icotinib hydrochloride were enrolled，median follow-up period was 21 months，data of efficacy and toxicity were recorded. ［Results］ The median progression-free survival (PFS) time was 8.1 months（95%CI：6.4～9.8months，the median overall survival (OS) time was 14.1 months (95%CI：11.5～16.7 months).The disease control rate was 71.6% (136/190)，the objective response rate was 35.3% (67/190). The median PFS of female with non-smoking was better than that of male with smoking. Patients with lower PS and treated with icotinib as multi-line treatments have a longer PFS and OS. The major toxicities were rash (38.9%)，diarrhea (13.7%)，transaminase elevation (11.1%) and epigastric discomfort (7.9%)，and only 1 case had pulmonary intestinal change. ［Conclusion］ Icotinib hydrochloride is effective and safe for Chinese patients with advanced NSCLC. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |